NetworkNewsBreaks – Sage Therapeutics, Inc. (NASDAQ: SAGE) Featured in Mizuho Securities Research Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Sage Therapeutics remains a controversial stock, with investors debating the regulatory path for zuranolone (SAGE-217). We continue to assume a 2023 launch in major depressive disorder as we expect Sage to do more dosing work and conduct at least one new Phase 3 trial. We present here proprietary analyses that further illustrate our view that differences seen with the 30mg dose in Phase 2 and Phase 3 were not simply due to chance, even if we exclude non-compliant…







